Table 1.
Demographic and clinical characteristics.
| Olanzapine | Risperidone | Quetiapine | Aripiprazole | Ziprasidone | Haploperidol | Perphenazine | |
|---|---|---|---|---|---|---|---|
| (N = 405) | (N = 404) | (N = 386) | (N = 392) | (N = 393) | (N = 184) | (N = 199) | |
| Sex | |||||||
| Male | 205 (50.6%) | 232 (57.4%) | 181 (46.9%) | 186 (47.4%) | 196 (49.9%) | 88 (47.8%) | 93 (46.7%) |
| Female | 200 (49.4%) | 172 (42.6%) | 205 (53.1%) | 206 (52.6%) | 197 (50.1%) | 96 (52.2%) | 106 (53.3%) |
| Age (years) | |||||||
| Mean (SD) | 30.1 (±7.89) | 30.5 (±7.91) | 30.7 (±7.76) | 31.0 (±7.82) | 30.2 (±7.99) | 32.7 (±7.63) | 31.9 (±8.04) |
| Family history | |||||||
| Without | 329 (81.2%) | 314 (77.7%) | 312 (80.8%) | 311 (79.3%) | 314 (79.9%) | 144 (78.3%) | 155 (77.9%) |
| With | 76 (18.8%) | 90 (22.3%) | 74 (19.2%) | 81 (20.7%) | 79 (20.1%) | 40 (21.7%) | 44 (22.1%) |
| Episode | |||||||
| Relapse | 291 (71.9%) | 278 (68.8%) | 283 (73.3%) | 278 (70.9%) | 284 (72.3%) | 138 (75.0%) | 147 (73.9%) |
| First episode | 114 (28.1%) | 126 (31.2%) | 103 (26.7%) | 114 (29.1%) | 109 (27.7%) | 46 (25.0%) | 52 (26.1%) |
| Duration (months) | |||||||
| Mean (SD) | 76.1 (±69.0) | 74.0 (±69.0) | 80.2 (±72.6) | 76.3 (±69.2) | 72.9 (±68.2) | 84.3 (±69.6) | 88.9 (±79.0) |
| Baseline PANSS score | |||||||
| Mean (SD) | 88.5 (±15.3) | 89.3 (±14.7) | 91.0 (±14.9) | 89.2 (±14.9) | 90.8 (±15.3) | 90.4 (±15.8) | 92.0 (±15.7) |